(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.

Monte Rosa Therapeutics (NASDAQ:GLUE), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The stando ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

After weeks of working with U.S. officials to try to avoid hefty tariffs on Swiss goods, negotiators from Switzerland got ...

Five major pharmaceutical companies are suing Oregon to stop a new state law that would expand how safety-net providers can ...

Novartis AG (NOVN.S) wants Roche Holding AG (ROG.S) to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according ...

Novartis AG NOVN -0.38% launched a lottery-style program to provide doses of its pricey gene therapy free of charge, drawing criticism from patient groups that called it an inappropriate way to ...

Novartis AG thinks its best bet for testing two new Alzheimer’s drugs is on people who don’t actually have Alzheimer’s. The Swiss drug giant is looking for people whose genes put them at ...